Ketamine Tablet Bioavailability Studies

The statement that ketamine tablet has 10–25% bioavailability is often cited in clinical and patient contexts, but understanding where this figure comes from, how it was measured, and why it varies matters for clinical decision-making. This article reviews the key pharmacokinetic studies that established these numbers.

How Bioavailability Is Measured

Bioavailability of an oral drug is measured by comparing the area under the plasma concentration-time curve (AUC) after oral administration to the AUC after IV administration of the same dose:

F = AUC(oral) / AUC(IV) × 100%

To obtain this ratio, researchers measure serial blood samples over many hours after administration, plot the plasma concentration over time, and compute the AUC for each route. The ratio gives the fraction of the oral dose that reached systemic circulation.

For ketamine, both the parent compound (ketamine) and its active metabolite (norketamine) must be measured to characterize the full pharmacokinetic profile. Our articles on peak plasma levels and first-pass metabolism explain how these measurements relate to clinical effects.

Landmark Pharmacokinetic Studies

Clements et al. (1982) — Seminal Study

This foundational pharmacokinetic study by Clements, Nimmo, and Grant at the University of Edinburgh was among the first to systematically characterize ketamine tablet pharmacokinetics in humans.

Study design: 10 healthy volunteers; ketamine tablet 0.5 mg/kg administered and blood samples collected for 8 hours; compared to IV administration

Key findings:

• Oral bioavailability of ketamine: approximately 16–20%
• Tmax: approximately 30 minutes (faster than expected due to rapid gastric emptying in volunteers)
• Norketamine plasma levels were significantly higher after oral than after IV administration, confirming the first-pass metabolic conversion

Significance: This study established the basic pharmacokinetic framework for ketamine tablet and identified the low bioavailability and high norketamine-to-ketamine ratio that characterize the oral route.

Limitations: Healthy volunteers (not patients); single dose; small sample

Malinovsky et al. (1996) — Pediatric Pharmacokinetics

A critically important study because ketamine tablet was first widely used in pediatric premedication. Malinovsky and colleagues studied ketamine tablet (6 mg/kg) as a premedication in 16 children undergoing surgery.

Key findings:

• Bioavailability in children: highly variable, ranging from approximately 16–29%
• Tmax: approximately 45–60 minutes
• Adequate sedation for premedication achieved in most children
• Substantial norketamine accumulation confirmed

Significance: Established that pediatric bioavailability was similar to adults but with high inter-individual variability.

Yanagihara et al. (2003) — Japanese Pharmacokinetic Study

This Japanese pharmacokinetic study examined multiple doses and routes in healthy volunteers, providing important comparative data.

Key findings:

• Oral bioavailability: approximately 20% (consistent with previous studies)
• Sublingual bioavailability: approximately 24% (modestly higher than oral swallowed)
• Half-life of ketamine tablet: approximately 2.8 hours
• Norketamine AUC after oral administration was approximately 2–3 times higher than ketamine AUC, confirming extensive first-pass conversion

Significance: Provided cleaner pharmacokinetic parameters across routes and confirmed the modest bioavailability advantage of sublingual over swallowed administration.

Wolff et al. (2009) — Comparative Route Study

Wolff and colleagues conducted a comprehensive comparison of multiple routes (IV, oral, nasal, sublingual) in healthy volunteers, providing the most systematic within-subject comparison available.

Routes studied: IV, oral, nasal spray, sublingual drops

Key findings:

Significance: This within-subject comparison provided the clearest data on relative bioavailability across routes, contributing to the understanding that nasal > sublingual > oral in terms of bioavailability.

Chong et al. (2009) — Australian Study with Food Effect

An Australian study examined ketamine pharmacokinetics with attention to food effects.

Key findings:

• Fasted oral bioavailability: approximately 20–25%
• With food (high-fat meal): bioavailability reduced to approximately 12–16% (blunted Cmax, delayed Tmax)
• Consistent with significant food-drug interaction affecting oral absorption

Significance: One of the most direct demonstrations of the food effect on ketamine tablet pharmacokinetics, supporting fasting recommendations for therapeutic sessions.

Factors Identified as Contributing to the 10–25% Range

The published studies collectively identify several sources of variability in ketamine tablet bioavailability:

Genetic Variability in CYP3A4

CYP3A4 is the most variable cytochrome P450 enzyme in the human population, with activity varying up to 40-fold between individuals. Studies have found that CYP3A4 poor metabolizers have higher ketamine tablet bioavailability (potentially 30%+) while ultra-rapid metabolizers have lower bioavailability (potentially <10%).

Formulation

Different oral formulations (solutions, capsules, tablets) have different dissolution characteristics and absorption rates, contributing to pharmacokinetic variability between studies that used different formulations.

Food Status

As documented by Chong et al. and consistent across studies, fasted vs. fed state can shift bioavailability by 30–50%, partially explaining within-individual variability when patients don't follow consistent fasting protocols.

Age

Reduced hepatic clearance in elderly patients results in higher effective bioavailability. Published data suggests elderly patients may have 30–40% higher ketamine exposure from the same oral dose compared to younger adults.

Concurrent Medications

CYP3A4 inhibitors (azole antifungals, macrolide antibiotics) dramatically increase ketamine tablet bioavailability by reducing first-pass metabolism. Inducers (carbamazepine, rifampin) reduce bioavailability. Studies conducted without controlling for these covariates will show greater variability.

Norketamine Pharmacokinetics: The Underappreciated Factor

A consistent finding across pharmacokinetic studies is that ketamine tablet generates substantially more norketamine — relative to ketamine — than IV administration:

• After IV dose: Norketamine AUC is typically 50–80% of ketamine AUC
• After oral dose: Norketamine AUC is typically 150–300% of ketamine AUC

This means that the "active drug exposure" after ketamine tablet includes a much larger norketamine component than after IV. Norketamine's own pharmacokinetics (longer half-life of 4–6 hours; lower NMDA receptor potency but distinct receptor interactions) contribute to the different clinical character of oral vs. IV ketamine experiences.

(2R,6R)-Hydroxynorketamine: Emerging Data

Recent research has begun characterizing the pharmacokinetics of (2R,6R)-hydroxynorketamine (HNK), a downstream norketamine metabolite identified as a potentially important antidepressant effector.

Preliminary data suggests that after ketamine tablet administration, HNK plasma concentrations are substantially higher than after IV administration — creating a pharmacokinetic profile enriched in this potentially important metabolite. This finding is being actively investigated and may ultimately explain why ketamine tablet's antidepressant effects, while different from IV, may have specific advantages for certain populations.

Clinical Implications of the Research

The pharmacokinetic research collectively informs clinical practice:

1. Dose calculations cannot assume proportional IV-to-oral conversion: The 10–25% variability means a dose that targets specific plasma levels must be individualized
2. Food timing protocols matter clinically: The documented food effect provides scientific basis for fasting recommendations
3. Elderly patients need dose reduction: Higher effective bioavailability in older adults is well-documented
4. Norketamine is not just a metabolite: It is an active pharmacological agent that should be considered in clinical decision-making
5. Formulation choice affects pharmacokinetics: Sublingual/buccal preparations modestly outperform swallowed tablets in bioavailability

References

• StatPearls: Ketamine — Comprehensive clinical reference on ketamine pharmacology, mechanisms of action, and therapeutic applications
• PubChem: Ketamine Compound Summary — NCBI chemical database entry with ketamine molecular data, pharmacokinetics, and bioactivity profiles
• MedlinePlus: Ketamine — National Library of Medicine consumer drug information on ketamine including uses, proper administration, and precautions
• SAMHSA: National Helpline — Substance Abuse and Mental Health Services Administration free treatment referral and information service